Kisqali ® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer

Formerly known as LEE011, Kisqali ® (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer i …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news